Molecular determinants of selective dopaminergic vulnerability in Parkinson’s disease: An update

Frontiers in Neuroanatomy

Volumn 8, Issue DEC, 2014, Pages

  Brichta, Lars ^a   Greengard, Paul ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Differential vulnerability; Dopamine; Parkinson s disease; Selective vulnerability; Substantia nigra; Ventral tegmental area

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; ALDEHYDE DEHYDROGENASE ISOENZYME 1; ALPHA SYNUCLEIN; CALBINDIN; CELL SURFACE RECEPTOR; DELETED IN COLORECTAL CANCER RECEPTOR; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 5 RECEPTOR; G PROTEIN COUPLED INWARDLY RECTIFYING POTASSIUM CHANNEL; LEVODOPA; MEMBRANE RECEPTOR; MESSENGER RNA; NETRIN; NUCLEAR RECEPTOR RELATED FACTOR 1; PROTEIN SERINE THREONINE KINASE; PTEN INDUCED PUTATIVE KINASE 1; RAB PROTEIN; REACTIVE OXYGEN METABOLITE; SODIUM CHANNEL; TRANSCRIPTION FACTOR OTX2; TRANSCRIPTION FACTOR PITX3; UNCLASSIFIED DRUG;

AGING; ARTICLE; BRAIN ASYMMETRY; CELL DIFFERENTIATION; CELL LOSS; CORPUS STRIATUM; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; ENZYME ACTIVATION; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LASER CAPTURE MICRODISSECTION; LEWY BODY; LOCUS CERULEUS; MESENCEPHALON; MOLECULAR DYNAMICS; NERVE DEGENERATION; NERVOUS SYSTEM ELECTROPHYSIOLOGY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SUBSTANTIA NIGRA PARS COMPACTA; VENTRAL TEGMENTUM;

EID: 84918771506     PISSN: None     EISSN: 16625129     Source Type: Journal    
DOI: 10.3389/fnana.2014.00152     Document Type: Article

References (155)

1. Afonso-Oramas, D., Cruz-Muros, I., Alvarez dela Rosa, D., Abreu, P., Giráldez, T., Castro-Hernandez, J., et al. (2009). Dopamine transporter glycosylation correlates with the vulnerability of midbrain dopaminergic cells in Parkinson’s disease. Neurobiol. Dis.36, 494–508. doi: 10.1016/j.nbd.2009.09.002
2. Airaksinen, M. S., Thoenen, H., and Meyer, M. (1997). Vulnerability of midbrain dopaminergic neurons in calbindin-D28k-deficient mice: lack of evidence for a neuroprotective role of endogenous calbindin in MPTP-treated and weaver mice. Eur. J. Neurosci.9, 120–127. doi: 10.1111/j.1460-9568.1997.tb01360.x
3. Albéri, L., Sgadò, P., and Simon, H. H. (2004). Engrailed genes are cell-autonomously required to prevent apoptosis in mesencephalic dopaminergic neurons. Development131, 3229–3236. doi: 10.1242/dev.01128
4. Alexianu, M. E., Ho, B. K., Mohamed, A. H., La Bella, V., Smith, R. G., and Appel, S. H. (1994). The role of calcium-binding proteins in selective motoneuron vulnerability in amyotrophic lateral sclerosis. Ann. Neurol.36, 846–858. doi: 10.1002/ana.410360608
5. Bäckman, C., Perlmann, T., Wallén, A., Hoffer, B. J., and Morales, M. (1999). A selective group of dopaminergic neurons express Nurr1 in the adult mouse brain. Brain Res. 851, 125–132. doi: 10.1016/s0006-8993(99)02149-6
6. Bender, A., Krishnan, K. J., Morris, C. M., Taylor, G. A., Reeve, A. K., Perry, R. H., et al. (2006). High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat. Genet.38, 515–517. doi: 10.1038/ng1769
7. Bender, A., Schwarzkopf, R. M., McMillan, A., Krishnan, K. J., Rieder, G., Neumann, M., et al. (2008). Dopaminergic midbrain neurons are the prime target for mitochondrial DNA deletions. J. Neurol.255, 1231–1235. doi: 10.1007/s00415-008-0892-9
8. Bentivoglio, M., and Morelli, M. (2005). “The organisation and circuits of mes-encephalic dopaminergic neurons and the distribution of dopamine receptors in the brain,” in Handbook of Chemical Neuroanatomy. (Dopamine), eds S. B. Dunnett, M. Bentivoglio, A. Bjorklund and T. Hokfelt (Elsevier), 21–107.
9. Bishop, M. W., Chakraborty, S., Matthews, G. A., Dougalis, A., Wood, N. W., Festenstein, R., et al. (2010). Hyperexcitable substantia nigra dopamine neurons in PINK1- and HtrA2/Omi-deficient mice. J. Neurophysiol.104, 3009–3020. doi: 10.1152/jn.00466.2010
10. Björklund, A., and Dunnett, S. B. (2007). Dopamine neuron systems in the brain: an update. Trends Neurosci. 30, 194–202. doi: 10.1016/j.tins.2007.03.006
11. Blesa, J., Juri, C., Garcia-Cabezas, M. A., Adanez, R., Sánchez-González, M. A., Cavada, C., et al. (2011). Inter-hemispheric asymmetry of nigrostriatal dopaminergic lesion: a possible compensatory mechanism in Parkinson’s disease. Front. Syst. Neurosci.5:92. doi: 10.3389/fnsys.2011.00092
12. Boillée, S., Vande Velde, C., and Cleveland, D. W. (2006). ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron 52, 39–59. doi: 10.1016/j.neuron.2006.09.018
13. Bolam, J. P., and Pissadaki, E. K. (2012). Living on the edge with too many mouthstofeed: why dopamine neurons die. Mov. Disord.27, 1478–1483. doi: 10.1002/mds.25135
14. Braak, H., Del Tredici, K., Rub, U., de Vos, R. A., Jansen Steur, E. N., and Braak, E. (2003). Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol. Aging24, 197–211. doi: 10.1016/s0197-4580(02)00065-9
15. Brichta, L., Greengard, P., and Flajolet, M. (2013). Advances in the pharmacological treatment of Parkinson’s disease: targeting neurotransmitter systems. TrendsNeurosci. 36, 543–554. doi: 10.1016/j.tins.2013.06.003
16. Brochier, C., Gaillard, M. C., Diguet, E., Caudy, N., Dossat, C., Ségurens, B., et al. (2008). Quantitative gene expression profiling of mouse brain regions reveals differential transcripts conserved in human and affected in disease models. Physiol. Genomics33, 170–179. doi: 10.1152/physiolgenomics.00125.2007
17. Burke, R. E., Dauer, W. T., and Vonsattel, J. P. (2008). A critical evaluation of the Braak staging scheme for Parkinson’s disease. Ann. Neurol.64, 485–491. doi: 10.1002/ana.21541
18. Cantuti-Castelvetri, I., Keller-McGandy, C., Bouzou, B., Asteris, G., Clark, T. W., Frosch, M. P., et al. (2007). Effects of gender on nigral gene expression and parkinson disease. Neurobiol. Dis. 26, 606–614. doi: 10.1016/j.nbd.2007.02.009
19. Castillo, S. O., Baffi, J. S., Palkovits, M., Goldstein, D. S., Kopin, I. J., Witta, J., et al. (1998). Dopamine biosynthesis is selectively abolished in substantia nigra/ventral tegmental area but not in hypothalamic neurons in mice with targeted disruption of the Nurr1 gene. Mol. Cell. Neurosci.11, 36–46. doi: 10.1006/mcne.1998.0673
20. Chan, C. S., Guzman, J. N., Ilijic, E., Mercer, J. N., Rick, C., Tkatch, T., et al. (2007). ‘Rejuvenation’ protects neurons in mouse models of Parkinson’s disease. Nature 447, 1081–1086. doi: 10.1038/nature05865
21. Chu, Y., Kompoliti, K., Cochran, E. J., Mufson, E. J., and Kordower, J. H. (2002). Age-related decreases in Nurr1 immunoreactivity in the human substantia nigra. J. Comp. Neurol.450, 203–214. doi: 10.1002/cne.10261
22. Chung, C. Y., Koprich, J. B., Endo, S., and Isacson, O. (2007). An endogenous serine/threonine protein phosphatase inhibitor, G-substrate, reduces vulnerability in models of Parkinson’s disease. J. Neurosci.27, 8314–8323. doi: 10.1523/jneurosci.1972-07.2007
23. Chung, C. Y., Koprich, J. B., Hallett, P. J., and Isacson, O. (2009). Functional enhancement and protection of dopaminergic terminals by RAB3B overex-pression. Proc. Natl. Acad. Sci. U S A 106, 22474–22479. doi: 10.1073/pnas.0912193106
24. Chung, C. Y., Licznerski, P., Alavian, K. N., Simeone, A., Lin, Z., Martin, E., et al. (2010). The transcription factor orthodenticle homeobox 2 influences axonal projections and vulnerability of midbrain dopaminergic neurons. Brain133, 2022–2031. doi: 10.1093/brain/awq142
25. Chung, C. Y., Seo, H., Sonntag, K. C., Brooks, A., Lin, L., and Isacson, O. (2005). Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection. Hum. Mol. Genet.14, 1709–1725. doi: 10.1093/hmg/ddi178
26. Collier, T. J., Lipton, J., Daley, B. F., Palfi, S., Chu, Y., Sortwell, C., et al. (2007). Aging-related changes in the nigrostriatal dopamine system and the response to MPTP in nonhuman primates: diminished compensatory mechanisms as a prelude to parkinsonism. Neurobiol. Dis. 26, 56–65. doi: 10.1016/j.nbd.2006.11.013
27. Cookson, M. R., and Bandmann, O. (2010). Parkinson’s disease: insights from pathways. Hum. Mol. Genet.19, R21–R27. doi: 10.1093/hmg/ddq167
28. Damier, P., Hirsch, E. C., Agid, Y., and Graybiel, A. M. (1999a). The substantia nigra of the human brain.I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. Brain122(Pt. 8), 1421–1436. doi: 10.1093/brain/122.8.1421
29. Damier, P., Hirsch, E. C., Agid, Y., and Graybiel, A. M. (1999b). The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson’s disease. Brain 122(Pt. 8), 1437–1448. doi: 10.1093/brain/122.8.1437
30. Dauer, W., and Przedborski, S. (2003). Parkinson’s disease: mechanisms and models. Neuron39, 889–909. doi: 10.1016/S0896-6273(03)00568-3
31. Di Giovannantonio, L. G., Di Salvio, M., Acampora, D., Prakash, N., Wurst, W., and Simeone, A. (2013). Otx2 selectively controls the neurogenesis of specific neu-ronal subtypes of the ventral tegmental area and compensates En1-dependent neuronal loss and MPTP vulnerability. Dev. Biol. 373, 176–183. doi: 10.1016/j.ydbio.2012.10.022
32. Di Salvio, M., Di Giovannantonio, L. G., Acampora, D., Prosperi, R., Omodei, D., Prakash, N., et al. (2010a). Otx2 controls neuron subtype identity in ventral tegmental area and antagonizes vulnerability to MPTP. Nat. Neurosci. 13, 1481–1488. doi: 10.1038/nn.2661
33. Di Salvio, M., Di Giovannantonio, L. G., Omodei, D., Acampora, D., and Simeone, A. (2010b). Otx2 expression is restricted to dopaminergic neurons of the ventral tegmental area in the adult brain. Int. J. Dev. Biol. 54, 939–945. doi: 10.1387/ijdb.092974ms
34. Djaldetti, R., Ziv, I., and Melamed, E. (2006). The mystery of motor asymmetry in Parkinson’s disease. Lancet Neurol. 5, 796–802. doi: 10.1016/s1474-4422(06)70549-x
35. Doyle, J. P., Dougherty, J. D., Heiman, M., Schmidt, E. F., Stevens, T. R., Ma, G., et al. (2008). Application of a translational profiling approach for the comparative analysis of CNS cell types. Cell135, 749–762. doi: 10.1016/j.cell.2008.10.029
36. Elstner, M., Muller, S. K., Leidolt, L., Laub, C., Krieg, L., Schlaudraff, F., et al. (2011). Neuromelanin, neurotransmitter status and brainstem location determine the differential vulnerability of catecholaminergic neurons to mitochon-drial DNA deletions. Mol. Brain4:43. doi: 10.1186/1756-6606-4-43
37. Emborg, M. E., Ma, S. Y., Mufson, E. J., Levey, A. I., Taylor, M. D., Brown, W. D., et al. (1998). Age-related declines in nigral neuronal function correlate with motor impairments in rhesus monkeys. J. Comp. Neurol. 401, 253–265. doi: 10.1002/(sici)1096-9861(19981116)401:2<253::aid-cne7>3.0.co;2-x
38. Endo, S., Shutoh, F., Dinh, T. L., Okamoto, T., Ikeda, T., Suzuki, M., et al. (2009). Dual involvement of G-substrate in motor learning revealed by gene deletion. Proc. Natl. Acad. Sci. U S A106, 3525–3530. doi: 10.1073/pnas.0813341106
39. Eulitz, D., Pruss, H., Derst, C., and Veh, R. W. (2007). Heterogeneous distribution of kir3 potassium channel proteins within dopaminergic neurons in the mesencephalon of the rat brain. Cell. Mol. Neurobiol.27, 285–302. doi: 10.1007/s10571-006-9118-9
40. Farrer, M., Kachergus, J., Forno, L., Lincoln, S., Wang, D. S., Hulihan, M., et al. (2004). Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann. Neurol.55, 174–179. doi: 10.1002/ana.10846
41. Fitzmaurice, A. G., Rhodes, S. L., Lulla, A., Murphy, N. P., Lam, H. A., O’Donnell, K. C., et al. (2013). Aldehyde dehydrogenase inhibition as a pathogenic mechanism in Parkinson disease. Proc. Natl. Acad. Sci. U S A110, 636–641. doi: 10.1073/pnas.1220399110
42. Fu, Y., Yuan, Y., Halliday, G., Rusznák, Z., Watson, C., and Paxinos, G. (2012). A cytoarchitectonic and chemoarchitectonic analysis of the dopamine cell groups in the substantia nigra, ventral tegmental area and retrorubral field in the mouse. Brain Struct. Funct.217, 591–612. doi: 10.1007/s00429-011-0349-2
43. Gao, L., Hidalgo-Figueroa, M., Escudero, L. M., Díaz-Martín, J., López-Barneo, J., and Pascual, A. (2013). Age-mediated transcriptomic changes in adult mouse substantia nigra. PLoS One8:e62456. doi: 10.1371/journal.pone.0062456
44. German, D. C., and Manaye, K. F. (1993). Midbrain dopaminergic neurons (nuclei A8, A9 and A10): three-dimensional reconstruction in the rat. J. Comp. Neurol.331, 297–309. doi: 10.1002/cne.903310302
45. German, D. C., Nelson, E. L., Liang, C. L., Speciale, S. G., Sinton, C. M., and Sonsalla, P. K. (1996). The neurotoxin MPTP causes degeneration of specific nucleus A8, A9and A10 dopaminergic neuronsinthe mouse. Neurodegeneration5, 299–312. doi: 10.1006/neur.1996.0041
46. Gouider-Khouja, N., Larnaout, A., Amouri, R., Sfar, S., Belal, S., Ben Hamida, C., et al. (2003). Autosomal recessive parkinsonism linked to parkin gene in a Tunisian family. Clinical, genetic and pathological study. Parkinsonism Relat. Disord.9, 247–251. doi: 10.1016/s1353-8020(03)00016-6
47. Graybiel, A. M., Ohta, K., and Roffler-Tarlov, S. (1990). Patterns of cell and fiber vulnerability in the mesostriatal system of the mutant mouse weaver. I. Gradients and compartments. J. Neurosci.10, 720–733.
48. Greene, J. G. (2006). Gene expression profiles of brain dopamine neurons and relevance to neuropsychiatric disease. J. Physiol. 575, 411–416. doi: 10.1113/jphysiol.2006.112599
49. Greene, J. G., Dingledine, R., and Greenamyre, J. T. (2005). Gene expression profiling of rat midbrain dopamine neurons: implications for selective vulnerability in parkinsonism. Neurobiol. Dis.18, 19–31. doi: 10.1016/j.nbd.2004.10.003
50. Greene, J. G., Dingledine, R., and Greenamyre, J. T. (2010). Neuron-selective changes in RNA transcripts related to energy metabolism in toxic models of parkinsonism in rodents. Neurobiol. Dis. 38, 476–481. doi: 10.1016/j.nbd.2010.03.014
51. Grimm, J., Mueller, A., Hefti, F., and Rosenthal, A. (2004). Molecular basis for catecholaminergic neuron diversity. Proc. Natl. Acad. Sci. U S A 101, 13891–13896. doi: 10.1073/pnas.0405340101
52. Guzman, J. N., Sanchez-Padilla, J., Wokosin, D., Kondapalli, J., Ilijic, E., Schumacker, P. T., et al. (2010). Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1. Nature468, 696–700. doi: 10.1038/nature09536
53. Halliday, G. M., McRitchie, D. A., Cartwright, H., Pamphlett, R., Hely, M. A., and Morris, J. G. (1996). Midbrain neuropathology in idiopathic Parkinson’s disease and diffuse Lewy body disease. J. Clin. Neurosci.3, 52–60. doi: 10.1016/s0967-5868(96)90083-1
54. Hasegawa, K., Stoessl, A. J., Yokoyama, T., Kowa, H., Wszolek, Z. K., and Yagishita, S. (2009). Familial parkinsonism: study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes. Parkinsonism Relat. Disord.15, 300–306. doi: 10.1016/j.parkreldis.2008.07.010
55. Heiman, M., Schaefer, A., Gong, S., Peterson, J. D., Day, M., Ramsey, K. E., et al. (2008). A translational profiling approach for the molecular characterization of CNS cell types. Cell135, 738–748. doi: 10.1016/j.cell.2008.10.028
56. Hirsch, E., Graybiel, A. M., and Agid, Y. A. (1988). Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson’s disease. Nature334, 345–348. doi: 10.1038/334345a0
57. Hirsch, E. C., Jenner, P., and Przedborski, S. (2013). Pathogenesis of Parkinson’s disease. Mov. Disord.28, 24–30. doi: 10.1002/mds.25032
58. Houlden, H., and Singleton, A. B. (2012). The genetics and neuropathology of Parkinson’s disease. Acta Neuropathol. 124, 325–338. doi: 10.1007/s00401-012-1013-5
59. Hwang, D. Y., Ardayfio, P., Kang, U. J., Semina, E. V., and Kim, K. S. (2003). Selective loss of dopaminergic neurons in the substantia nigra of Pitx3-deficient aphakia mice. Brain Res. Mol. Brain Res.114, 123–131. doi: 10.1016/s0169-328x(03)00162-1
60. Jackson-Lewis, V., Jakowec, M., Burke, R. E., and Przedborski, S. (1995). Time course and morphology of dopaminergic neuronal death caused by the neuro-toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 4, 257–269. doi: 10.1016/1055-8330(95)90015-2
61. Jackson-Lewis, V., and Przedborski, S. (2007). Protocol for the MPTP mouse model of Parkinson’s disease. Nat. Protoc.2, 141–151. doi: 10.1038/nprot.2006.342
62. Kadkhodaei, B., Alvarsson, A., Schintu, N., Ramsköld, D., Volakakis, N., Joodmardi, E., et al. (2013). Transcription factor Nurr1 maintains fiber integrity and nuclear-encoded mitochondrial gene expression in dopamine neurons. Proc. Natl. Acad. Sci. U S A110, 2360–2365. doi: 10.1073/pnas.1221077110
63. Kadkhodaei, B., Ito, T., Joodmardi, E., Mattsson, B., Rouillard, C., Carta, M., et al. (2009). Nurr1 is required for maintenance of maturing and adult midbrain dopamine neurons. J. Neurosci. 29, 15923–15932. doi: 10.1523/JNEUROSCI.3910-09.2009
64. Kanaan, N. M., Kordower, J. H., and Collier, T. J. (2007). Age-related accumulation of Marinesco bodies and lipofuscin in rhesus monkey midbrain dopamine neurons: relevance to selective neuronal vulnerability. J. Comp. Neurol. 502, 683–700. doi: 10.1002/cne.21333
65. Kanaan, N. M., Kordower, J. H., and Collier, T. J. (2008). Age-related changes in dopamine transporters and accumulation of 3-nitrotyrosine in rhesus monkey midbrain dopamine neurons: relevance in selective neuronal vulnerability to degeneration. Eur. J. Neurosci. 27, 3205–3215. doi: 10.1111/j.1460-9568.2008.06307.x
66. Kempster, P. A., Gibb, W. R., Stern, G. M., and Lees, A. J. (1989). Asymmetry of substantia nigra neuronal loss in Parkinson’s disease and its relevance to the mechanism of levodopa related motor fluctuations. J. Neurol. Neurosurg. Psychiatry52, 72–76. doi: 10.1136/jnnp.52.1.72
67. Kihira, T., Yoshida, S., Yoshimasu, F., Wakayama, I., and Yase, Y. (1997). Involvement of Onuf’s nucleus in amyotrophic lateral sclerosis. J. Neurol. Sci. 147, 81–88. doi: 10.1016/s0022-510x(96)05313-0
68. Kobayashi, T., and Ikeda, K. (2006). G protein-activated inwardly rectifying potassium channels as potential therapeutic targets. Curr. Pharm. Des.12, 4513–4523. doi: 10.2174/138161206779010468
69. Kordower, J. H., Chu, Y., Hauser, R. A., Freeman, T. B., and Olanow, C. W. (2008a). Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson’s disease. Nat. Med.14, 504–506. doi: 10.1038/nm1747
70. Kordower, J. H., Chu, Y., Hauser, R. A., Olanow, C. W., and Freeman, T. B. (2008b). Transplanted dopaminergic neurons develop PD pathologic changes: a second case report. Mov. Disord. 23, 2303–2306. doi: 10.1002/mds.22369
71. Kordower, J. H., Olanow, C. W., Dodiya, H. B., Chu, Y., Beach, T. G., Adler, C. H., et al. (2013). Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease. Brain136, 2419–2431. doi: 10.1093/brain/awt192
72. Korotkova, T. M., Ponomarenko, A. A., Haas, H. L., and Sergeeva, O. A. (2005). Differential expression of the homeobox gene Pitx3 in midbrain dopaminer-gic neurons. Eur. J. Neurosci. 22, 1287–1293. doi: 10.1111/j.1460-9568.2005.04327.x
73. Kraytsberg, Y., Kudryavtseva, E., McKee, A. C., Geula, C., Kowall, N. W., and Khrapko, K. (2006). Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. Nat. Genet.38, 518–520. doi: 10.1038/ng1778
74. Lammel, S., Hetzel, A., Häckel, O., Jones, I., Liss, B., and Roeper, J. (2008). Unique properties of mesoprefrontal neurons within a dual mesocorticolimbic dopamine system. Neuron57, 760–773. doi: 10.1016/j.neuron.2008.01.022
75. Le Masson, G., Przedborski, S., and Abbott, L. F. (2014). A computational model of motor neuron degeneration. Neuron 83, 975–988. doi: 10.1016/j.neuron.2014.07.001
76. Li, L. B., Chen, N., Ramamoorthy, S., Chi, L., Cui, X. N., Wang, L. C., et al. (2004). The role of N-glycosylation in function and surface trafficking of the human dopamine transporter. J. Biol. Chem.279, 21012–21020. doi: 10.1074/jbc.m311972200
77. Li, J., Duarte, T., Kocabas, A., Works, M., McConnell, S. K., and Hynes, M. A. (2014). Evidence for topographic guidance of dopaminergic axons by differential Netrin-1 expression in the striatum. Mol. Cell. Neurosci.61, 85–96. doi: 10.1016/j.mcn.2014.05.003
78. Li, J. Y., Englund, E., Holton, J. L., Soulet, D., Hagell, P., Lees, A. J., et al. (2008). Lewy bodies in grafted neurons in subjects with Parkinson’s disease suggest host-to-graft disease propagation. Nat. Med.14, 501–503. doi: 10.1038/nm1746
79. Liang, C. L., Sinton, C. M., and German, D. C. (1996). Midbrain dopaminergic neurons in the mouse: co-localization with Calbindin-D28K and calretinin. Neuroscience75, 523–533. doi: 10.1016/0306-4522(96)00228-x
80. Liang, C. L., Wang, T. T., Luby-Phelps, K., and German, D. C. (2007). Mitochondria mass is low in mouse substantia nigra dopamine neurons: implications for Parkinson’s disease. Exp. Neurol. 203, 370–380. doi: 10.1016/j.expneurol.2006.08.015
81. Lin, X., Parisiadou, L., Sgobio, C., Liu, G., Yu, J., Sun, L., et al. (2012). Conditional expression of Parkinson’s disease-related mutant alpha-synuclein in the midbrain dopaminergic neurons causes progressive neurodegeneration and degradation of transcription factor nuclear receptor related 1. J. Neurosci.32, 9248–9264. doi: 10.1523/JNEUROSCI.1731-12.2012
82. Liss, B., Haeckel, O., Wildmann, J., Miki, T., Seino, S., and Roeper, J. (2005). K-ATP channels promote the differential degeneration of dopaminergic midbrain neurons. Nat. Neurosci.8, 1742–1751. doi: 10.1038/nn1570
83. Liu, F. C., and Graybiel, A. M. (1992). Transient calbindin-D28k-positive systems in the telencephalon: ganglionic eminence, developing striatum and cerebral cortex. J. Neurosci.12, 674–690.
84. Liu, G., Yu, J., Ding, J., Xie, C., Sun, L., Rudenko, I., et al. (2014). Aldehyde dehydrogenase 1 defines and protects a nigrostriatal dopaminergic neuron subpopulation. J. Clin. Invest.124, 3032–3046. doi: 10.1172/JCI72176
85. Livesey, F. J., and Hunt, S. P. (1997). Netrin and netrin receptor expression in the embryonic mammalian nervous system suggests roles in retinal, striatal, nigral and cerebellar development. Mol. Cell. Neurosci. 8, 417–429. doi: 10.1006/mcne.1997.0598
86. Lu, L., Neff, F., Dun, Z., Hemmer, B., Oertel, W. H., Schlegel, J., et al. (2004). Gene expression profiles derived from single cells in human postmortem brain. Brain Res. Brain Res. Protoc.13, 18–25. doi: 10.1016/j.brainresprot.2003.12.003
87. Luk, K. C., Kehm, V., Carroll, J., Zhang, B., O’Brien, P., Trojanowski, J. Q., et al. (2012). Pathological α-synuclein transmission initiates Parkinson-like neurode-generation in nontransgenic mice. Science 338, 949–953. doi: 10.1126/science.1227157
88. Luk, K. C., Rymar, V. V., van den Munckhof, P., Nicolau, S., Steriade, C., Bifsha, P., et al. (2013). The transcription factor Pitx3 is expressed selectively in midbrain dopaminergic neurons susceptible to neurodegenerative stress. J. Neurochem.125, 932–943. doi: 10.1111/jnc.12160
89. Marchitti, S. A., Deitrich, R. A., and Vasiliou, V. (2007). Neurotoxicity and metabolism of the catecholamine-derived 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylglycolaldehyde: the role of aldehyde dehydrogenase. Pharmacol. Rev.59, 125–150. doi: 10.1124/pr.59.2.1
90. Martí, J., Santa-Cruz, M. C., Bayer, S. A., Ghetti, B., and Hervás, J. P. (2007). Generation and survival of midbrain dopaminergic neurons in weaver mice. Int. J. Dev. Neurosci.25, 299–307. doi: 10.1016/j.ijdevneu.2007.05.002
91. Martí, J., Wills, K. V., Ghetti, B., and Bayer, S. A. (2000). The weaver gene continues to target late-generated dopaminergic neurons in midbrain areas at P90. Brain Res. Dev. Brain Res.122, 173–181. doi: 10.1016/s0165-3806(00)00071-7
92. Matsumoto, M., and Hikosaka, O. (2009). Twotypes of dopamine neuron distinctly convey positive and negative motivational signals. Nature459, 837–841. doi: 10.1038/nature08028
93. McCaffery, P., and Dräger, U. C. (1994). High levels of a retinoic acid-generating dehydrogenase in the meso-telencephalic dopamine system. Proc. Natl. Acad. Sci. U S A91, 7772–7776. doi: 10.1073/pnas.91.16.7772
94. McCormack, A. L., Di Monte, D. A., Delfani, K., Irwin, I., Delanney, L. E., Langston, W. J., et al. (2004). Aging of the nigrostriatal system in the squirrel monkey. J.Comp. Neurol.471, 387–395. doi: 10.1002/cne.20036
95. McRitchie, D. A., Cartwright, H. R., and Halliday, G. M. (1997). Specific A10 dopaminergic nuclei in the midbrain degenerate in Parkinson’s disease. Exp. Neurol.144, 202–213. doi: 10.1006/exnr.1997.6418
96. Mendez, I., Sanchez-Pernaute, R., Cooper, O., Viñuela, A., Ferrari, D., Bjorklund, L., et al. (2005). Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson’s disease. Brain128, 1498–1510. doi: 10.1093/brain/awh510
97. Mercuri, N. B., Bonci, A., Calabresi, P., Stratta, F., Stefani, A., and Bernardi, G. (1994). Effects of dihydropyridine calcium antagonists on rat midbrain dopaminergic neurones. Br. J. Pharmacol.113, 831–838. doi: 10.1111/j.1476-5381.1994.tb17068.x
98. Mori, H., Kondo, T., Yokochi, M., Matsumine, H., Nakagawa-Hattori, Y., Miyake, T., et al. (1998). Pathologic and biochemical studies of juvenile parkinson-ism linked to chromosome 6q. Neurology 51, 890–892. doi: 10.1212/wnl.51.3.890
99. Morrison, J. H., and Hof, P. R. (2002). Selective vulnerability of corticocortical and hippocampal circuits in aging and Alzheimer’s disease. Prog. Brain Res. 136, 467– 486. doi: 10.1016/s0079-6123(02)36039-4
100. Morrison, J. H., and Hof, P. R. (2007). Life and death of neurons in the aging cerebral cortex. Int. Rev. Neurobiol.81, 41–57. doi: 10.1016/s0074-7742(06)81004-4
101. Mosharov, E. V., Larsen, K. E., Kanter, E., Phillips, K. A., Wilson, K., Schmitz, Y., et al. (2009). Interplay between cytosolic dopamine, calcium and alpha-synuclein causes selective death of substantia nigra neurons. Neuron 62, 218–229. doi: 10.1016/j.neuron.2009.01.033
102. Muthane, U., Ramsay, K. A., Jiang, H., Jackson-Lewis, V., Donaldson, D., Fernando, S., et al. (1994). Differences in nigral neuron number and sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57/bl and CD-1 mice. Exp. Neurol.126, 195–204. doi: 10.1006/exnr.1994.1058
103. Nair-Roberts, R. G., Chatelain-Badie, S. D., Benson, E., White-Cooper, H., Bolam, J. P., and Ungless, M. A. (2008). Stereological estimates of dopaminergic, GABAergic and glutamatergic neurons in the ventral tegmental area, substantia nigra and retrorubral field in the rat. Neuroscience152, 1024–1031. doi: 10.1016/j.neuroscience.2008.01.046
104. Nedergaard, S., Flatman, J. A., and Engberg, I. (1993). Nifedipine- and omega-conotoxin-sensitive Ca2+ conductances in guinea-pig substantia nigra pars compacta neurones. J. Physiol.466, 727–747.
105. Nelson, E. L., Liang, C. L., Sinton, C. M., and German, D. C. (1996). Midbrain dopaminergic neurons in the mouse: computer-assisted mapping. J. Comp. Neurol. 369, 361–371. doi: 10.1002/(sici)1096-9861(19960603)369:3<361::aid-cne3>3.0.co;2-3
106. Neuhoff, H., Neu, A., Liss, B., and Roeper, J. (2002). I(h) channels contribute to the different functional properties of identified dopaminergic subpopulations in the midbrain. J. Neurosci.22, 1290–1302.
107. Nordström, U., Beauvais, G., Ghosh, A., Pulikkaparambil Sasidharan, B. C., Lund-blad, M., Fuchs, J., et al. (2014). Progressive nigrostriatal terminal dysfunction and degeneration in the engrailed1 heterozygous mouse model of Parkinson’s disease. Neurobiol. Dis. doi: 10.1016/j.nbd.2014.09.012. [Epub ahead of print].
108. Nunes, I., Tovmasian, L. T., Silva, R. M., Burke, R. E., and Goff, S. P. (2003). Pitx3 is required for development of substantia nigra dopaminergic neurons. Proc. Natl. Acad. Sci. U S A100, 4245–4250. doi: 10.1073/pnas.0230529100
109. Omodei, D., Acampora, D., Mancuso, P., Prakash, N., Di Giovannantonio, L. G., Wurst, W., et al. (2008). Anterior-posterior graded response to Otx2 controls proliferation and differentiation of dopaminergic progenitors in the ventral mesencephalon. Development135, 3459–3470. doi: 10.1242/dev.027003
110. Osborne, P. B., Halliday, G. M., Cooper, H. M., and Keast, J. R. (2005). Localization of immunoreactivity for deleted in colorectal cancer (DCC), the receptor for the guidance factor netrin-1, in ventral tier dopamine projection pathways in adult rodents. Neuroscience131, 671–681. doi: 10.1016/j.neuroscience.2004.11.043
111. Pan, P. Y., and Ryan, T. A. (2012). Calbindin controls release probability in ventral tegmental area dopamine neurons. Nat. Neurosci. 15, 813–815. doi: 10.1038/nn.3099
112. Patil, N., Cox, D. R., Bhat, D., Faham, M., Myers, R. M., and Peterson, A. S. (1995). A potassium channel mutation in weaver mice implicates membrane excitability in granule cell differentiation. Nat. Genet.11, 126–129. doi: 10.1038/ng1095-126
113. Phani, S., Gonye, G., and Iacovitti, L. (2010). VTA neurons show a potentially protective transcriptional response to MPTP. Brain Res. 1343, 1–13. doi: 10.1016/j.brainres.2010.04.061
114. Phani, S., Jablonski, M., Pelta-Heller, J., Cai, J., and Iacovitti, L. (2013). Gremlin is a novel VTA derived neuroprotective factor for dopamine neurons. Brain Res. 1500, 88–98. doi: 10.1016/j.brainres.2013.01.017
115. Pissadaki, E. K., and Bolam, J. P. (2013). The energy cost of action potential propagation in dopamine neurons: clues to susceptibility in Parkinson’s disease. Front. Comput. Neurosci.7:13. doi: 10.3389/fncom.2013.00013
116. Pramstaller, P. P., Schlossmacher, M. G., Jacques, T. S., Scaravilli, F., Eskelson, C., Pepivani, I., et al. (2005). Lewy body Parkinson’s disease in a large pedigree with 77 Parkin mutation carriers. Ann. Neurol.58, 411–422. doi: 10.1002/ana.20587
117. Reyes, S., Cottam, V., Kirik, D., Double, K. L., and Halliday, G. M. (2013a). Variability in neuronal expression of dopamine receptors and transporters in the substantia nigra. Mov. Disord. 28, 1351–1359. doi: 10.1002/mds.25493
118. Reyes, S., Fu, Y., Double, K. L., Cottam, V., Thompson, L. H., Kirik, D., et al. (2013b). Trophic factors differentiate dopamine neurons vulnerable to Parkinson’s disease. Neurobiol. Aging 34, 873–886. doi: 10.1016/j.neurobiolaging.2012.07.019
119. Reyes, S., Fu, Y., Double, K., Thompson, L., Kirik, D., Paxinos, G., et al. (2012). GIRK2 expression in dopamine neurons of the substantia nigra and ventral tegmental area. J. Comp. Neurol.520, 2591–2607. doi: 10.1002/cne.23051
120. Rousseaux, M. W., Marcogliese, P. C., Qu, D., Hewitt, S. J., Seang, S., Kim, R. H., et al. (2012). Progressive dopaminergic cell loss with unilateral-to-bilateral progression in a genetic model of Parkinson disease. Proc. Natl. Acad. Sci. U S A109, 15918–15923. doi: 10.1073/pnas.1205102109
121. Saucedo-Cardenas, O., Quintana-Hau, J. D., Le, W. D., Smidt, M. P., Cox, J. J., De Mayo, F., et al. (1998). Nurr1 is essential for the induction of the dopaminergic phenotype and the survival of ventral mesencephalic late dopaminergic precursor neurons. Proc. Natl. Acad. Sci. U S A 95, 4013–4018. doi: 10.1073/pnas.95.7.4013
122. Schein, J. C., Hunter, D. D., and Roffler-Tarlov, S. (1998). Girk2 expression in the ventral midbrain, cerebellum and olfactory bulb and its relationship to the murine mutation weaver. Dev. Biol.204, 432–450. doi: 10.1006/dbio.1998.9076
123. Schiemann, J., Schlaudraff, F., Klose, V., Bingmer, M., Seino, S., Magill, P. J., et al. (2012). K-ATP channels in dopamine substantia nigra neurons control bursting and novelty-induced exploration. Nat. Neurosci.15, 1272–1280. doi: 10.1038/nn.3185
124. Semina, E. V., Murray, J. C., Reiter, R., Hrstka, R. F., and Graw, J. (2000). Deletion in the promoter region and altered expression of Pitx3 homeobox gene in aphakia mice. Hum. Mol. Genet.9, 1575–1585. doi: 10.1093/hmg/9.11.1575
125. Seniuk, N. A., Tatton, W. G., and Greenwood, C. E. (1990). Dose-dependent destruction of the coeruleus-cortical and nigral-striatal projections by MPTP. Brain Res. 527, 7–20. doi: 10.1016/0006-8993(90)91055-l
126. Sgadò, P., Albéri, L., Gherbassi, D., Galasso, S. L., Ramakers, G. M., Alavian, K. N., et al. (2006). Slow progressive degeneration of nigral dopaminergic neurons in postnatal Engrailed mutant mice. Proc. Natl. Acad. Sci. U S A103, 15242–15247. doi: 10.1073/pnas.0602116103
127. Simon, H. H., Saueressig, H., Wurst, W., Goulding, M. D., and O’Leary, D. D. (2001). Fate of midbrain dopaminergic neurons controlled by the engrailed genes. J. Neurosci.21, 3126–3134.
128. Simunovic, F., Yi, M., Wang, Y., Macey, L., Brown, L. T., Krichevsky, A. M., et al. (2009). Gene expression profiling ofsubstantia nigra dopamine neurons: further insights into Parkinson’s disease pathology. Brain132, 1795–1809. doi: 10.1093/brain/awn323
129. Singleton, A. B., Farrer, M. J., and Bonifati, V. (2013). The genetics of Parkinson’s disease: progress and therapeutic implications. Mov. Disord.28, 14–23. doi: 10.1002/mds.25249
130. Sirinathsinghji, D. J., Kupsch, A., Mayer, E., Zivin, M., Pufal, D., and Oertel, W. H. (1992). Cellular localization of tyrosine hydroxylase mRNA and cholecystokinin mRNA-containing cells in the ventral mesencephalon of the common marmoset: effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Brain Res. Mol. Brain Res.12, 267–274. doi: 10.1016/0169-328x(92)90093-q
131. Smidt, M. P., Smits, S. M., and Burbach, J. P. (2003). Molecular mechanisms underlying midbrain dopamine neuron development and function. Eur. J. Pharmacol.480, 75–88. doi: 10.1016/j.ejphar.2003.08.094
132. Smits, S. M., von Oerthel, L., Hoekstra, E. J., Burbach, J. P., and Smidt, M. P. (2013). Molecular marker differences relate to developmental position and subsetsof mesodiencephalic dopaminergic neurons. PLoS One8:e76037. doi: 10.1371/journal.pone.0076037
133. Sonnier, L., Le Pen, G., Hartmann, A., Bizot, J. C., Trovero, F., Krebs, M. O., et al. (2007). Progressive loss of dopaminergic neurons in the ventral midbrain of adult mice heterozygote for Engrailed1. J. Neurosci.27, 1063–1071. doi: 10.1523/jneurosci.4583-06.2007
134. Spillantini, M. G., Schmidt, M. L., Lee, V. M., Trojanowski, J. Q., Jakes, R., and Goedert, M. (1997). Alpha-synuclein in Lewy bodies. Nature388, 839–840. doi: 10.1038/42166
135. Spira, P. J., Sharpe, D. M., Halliday, G., Cavanagh, J., and Nicholson, G. A. (2001). Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr α-synuclein mutation. Ann. Neurol.49, 313–319. doi: 10.1002/ana.67
136. Stein, E., Zou, Y., Poo, M., and Tessier-Lavigne, M. (2001). Binding of DCC by netrin-1 to mediate axon guidance independent of adenosine A2B receptor activation. Science291, 1976–1982. doi: 10.1126/science.1059391
137. Stranahan, A. M., and Mattson, M. P. (2010). Selective vulnerability of neurons in layer II of the entorhinal cortex during aging and Alzheimer’s disease. NeuralPlast. 2010:108190. doi: 10.1155/2010/108190
138. Surmeier, D. J., Guzman, J. N., Sanchez-Padilla, J., and Goldberg, J. A. (2010). What causes the death of dopaminergic neurons in Parkinson’s disease? Prog. Brain Res.183, 59–77. doi: 10.1016/s0079-6123(10)83004-3
139. Talbot, K. (2014). Amyotrophic lateral sclerosis: cell vulnerability or system vulnerability? J. Anat.224, 45–51. doi: 10.1111/joa.12107
140. Talbot, K., and Davies, K. E. (2001). Spinal muscular atrophy. Semin. Neurol.21, 189–197. doi: 10.1055/s-2001-15264
141. Thompson, L., Barraud, P., Andersson, E., Kirik, D., and Björklund, A. (2005). Identification of dopaminergic neurons of nigral and ventral tegmental area subtypes in grafts of fetal ventral mesencephalon based on cell morphology, protein expression and efferent projections. J. Neurosci.25, 6467–6477. doi: 10.1523/jneurosci.1676-05.2005
142. Triarhou, L. C., Norton, J., and Ghetti, B. (1988). Mesencephalic dopamine cell deficit involves areas A8, A9 and A10 in weaver mutant mice. Exp. Brain Res.70, 256–265. doi: 10.1007/bf00248351
143. Tritsch, N. X., Ding, J. B., and Sabatini, B. L. (2012). Dopaminergic neurons inhibit striatal output through non-canonical release of GABA. Nature490, 262–266. doi: 10.1038/nature11466
144. Tsetsenis, T., Younts, T. J., Chiu, C. Q., Kaeser, P. S., Castillo, P. E., and Südhof, T. C. (2011). Rab3B protein is required for long-term depression of hippocampal inhibitory synapses and for normal reversal learning. Proc. Natl. Acad. Sci. U S A 108, 14300–14305. doi: 10.1073/pnas.1112237108
145. van den Munckhof, P., Luk, K. C., Ste-Marie, L., Montgomery, J., Blanchet, P. J., Sadikot, A. F., et al. (2003). Pitx3 is required for motor activity and for survival of a subset of midbrain dopaminergic neurons. Development130, 2535–2542. doi: 10.1242/dev.00464
146. Varastet, M., Riche, D., Maziere, M., and Hantraye, P. (1994). Chronic MPTP treatment reproduces in baboons the differential vulnerability of mesencephalic dopaminergic neurons observed in Parkinson’s disease. Neuroscience63, 47–56. doi: 10.1016/0306-4522(94)90006-x
147. Verney, C., Febvret-Muzerelle, A., and Gaspar, P. (1995). Early postnatal changes of the dopaminergic mesencephalic neurons in the weaver mutant mouse. Brain Res. Dev. Brain Res. 89, 115–119. doi: 10.1016/0165-3806(95) 00106-n
148. von Lewinski, F., and Keller, B. U. (2005). Ca2+, mitochondria and selective motoneuron vulnerability: implications for ALS. Trends Neurosci. 28, 494–500. doi: 10.1016/j.tins.2005.07.001
149. Watabe-Uchida, M., Zhu, L., Ogawa, S. K., Vamanrao, A., and Uchida, N. (2012). Whole-brain mapping of direct inputs to midbrain dopamine neurons. Neuron74, 858–873. doi: 10.1016/j.neuron.2012.03.017
150. Wolfart, J., Neuhoff, H., Franz, O., and Roeper, J. (2001). Differential expression of the small-conductance, calcium-activated potassium channel SK3 is critical for pacemaker control in dopaminergic midbrain neurons. J. Neurosci.21, 3443–3456.
151. Zarow, C., Lyness, S. A., Mortimer, J. A., and Chui, H. C. (2003). Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch. Neurol.60, 337–341. doi: 10.1001/archneur.60.3.337
152. Zarranz, J. J., Alegre, J., Gómez-Esteban, J. C., Lezcano, E., Ros, R., Ampuero, I., et al. (2004). The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol.55, 164–173. doi: 10.1002/ana.10795
153. Zetterström, R. H., Solomin, L., Jansson, L., Hoffer, B. J., Olson, L., and Perlmann, T. (1997). Dopamine neuron agenesis in Nurr1-deficient mice. Science276, 248–250. doi: 10.1126/science.276.5310.248
154. Zheng, B., Liao, Z., Locascio, J. J., Lesniak, K. A., Roderick, S. S., Watt, M. L., et al. (2010). PGC-1α, a potential therapeutic target for early intervention in Parkinson’s disease. Sci. Transl. Med. 2:52ra73. doi: 10.1126/scitranslmed.3001059
155. Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., et al. (2004). Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron44, 601–607. doi: 10.1016/j.neuron.2004.11.005